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The etiological agent of Newcastle disease, Newcastle disease virus ( NDV), a 
member of the family Paramyxoviridae and the genus of Rubulavirus, can cause up to 
100% morbidity and mortality. Immune responses to both the fusion ( F) and 
haemagglutinin-neuraminidase (HN) protein antigens of NDV were demonstrated to 
play an important role in the prevention of infection. Towards development of DNA 
vaccine, both the F and HN genes of a Malaysian heat resistant viscerotropic-
velogenic NDV strain AF2240 were amplified and cloned into a mammalian 
expression vector, pEGFP-Ns, and expressed in a mammalian cell line under the 
control of the immediate early promoter of human cytomegalovirus. 
Six recombinant plasmids were constructed, namely pEGFP-N31F, -NIIHN, -
N31HN-GFP, -N2IFkoz, -N2lHNkoz and -NIIFkoz-GFP with the later three 
constructs introduced with the kozak translation initiation sequences. Transient 
expression of F and HN proteins was assayed in vitro in Vero cell at 48 h post-
transfection by indirect immunofluorescence using NDV polyclonal antibody and 
III 
fluorescein isothiocyanate (FITC)-labelled anti-chicken IgG. The results showed that 
all the DNA-transfected cells exhibited bright cytoplasmic fluorescene, indicating 
both the F and HN proteins were successfully expressed in the mammalian cell line. 
Immunoblot analysis of the transfected cell lysates further verified the presence of the 
recombinant proteins with a distinct band of 64 kDa which corresponds to the 
uncleaved precusor Fo glycoprotein of NDV and two bands of -62 and 72 kDa as 
unglycosylated and glycosylated HN glycoproteins, respectively. eSS]-methionine 
pulsed labelling of transfected cells confirmed the expression of green fluorescent 
protein (GFP)-fusion protein of F, but not HN-GFP. 
DNA inoculation in Balb/c mice and specific pathogen free (SPF) chicken 
revealed that the efficacy of DNA vaccines could be boosted by co-administration of 
Freund's adjuvant and repeating DNA immunization. The vaccine trial in SPF 
chickens showed that both the circular and linearized plasmid DNA of pEGFP-N3IF 
produced significant levels of antibody against NDV after the second booster and 
conferred 40-47% protection upon lethal NOV challenge. Co-administration of the 
circular plasmids of pEGFP-N3/F and -NIIHN, produced antibodies efficiently and 
conferred more than 50% protection upon NOV challenge. The low and undetectable 
antibody level in some of the survivors suggests that DNA vaccine elicits cellular 
immune response in chicken. The overall results also suggest that both the F and HN­
DNA can be used as a vaccine component to provide effective protection against 
NDV and DNA immunization opens a new approach to the development of gene 
vaccine for chicken against infectious disease. 
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Agen etiologi penyakit Newcastle, iaitu vi�s penyakit Newcastle (NDV), 
anggota famili Paramyxoviridae dan genus Rubulavirus, boleh menyebabkan 100% 
morbiditi dan mortaliti. Reaksi keimunan terhadap antigen-antigen protein pertaupan 
(F) dan hemaglutinin-neuraminidase (HN) NDV memainkan peranan yang penting 
dalam pencegahan jankitan. Untuk menghasilkan vaksin DNA, kedua-dua gen F dan 
HN strain AF2240 NDV Malaysia yang velogenik viserotropik telah diamplifikasikan 
and diklonkan ke dalam vector pengekspresan mamalia, pEGFP-Ns, dan diekspreskan 
dalam sel mamalia di bawah pengaruh promoter sitomegalovirus manusia. 
Enam plasmid rekombinan telah dibina, iaitu pEGFP-N31F, -N11HN, -N31HN-
GFP, -N2IFkoz, -N2lHNkoz dan -NIlFkoz-GFP dengan ketiga-tiga plasmid terakhir 
disertakan dengan jujukan permulan penterjemahan kozak. Pengekspresan sementara 
bagi protein-protein F and HN telah diesei secara in vitro dalam sel Vero 48 jam 
selepas proses transfeksi oleh imunopendarfluoran dengan menggunakan antibodi 
poliklonal NDV dan IgG anti-ayam berlabel pendarfluoran isothiosinat (FITC). 
v 
Keputusan menunjukkan kesemua sel yang ditranfeksikan DNA memberi pendarfluor 
sitoplasmik, menandakan kedua-dua protein F dan HN telah diekspreskan dalam sel 
mamalia Analisis imunoblot bagi lisat sel transfeksi menunjukkan kahadiran jalur 
protein rekombinan pada 64 kDa yang berpadan dengan protein prekursor Fo NDV 
tidak terpotong dan dua jalur protein pada -62 dan 72 kDa sebagai HN glikoprotein 
yang tidak berglikosilasi dan berglikosilasi masing-masing. Sel-sel transfeksi yang 
berlabel dengan eSS]-methionin menunjukkan pengekspresan protein pendarfluoran 
hijau (GFP) bertaupan dengan F, tetapi bukan GFP-HN. 
Inokulasi DNA dalam tikus Balb/c dan ayam pathogen bebas spesifik (SPF) 
menunjukkan keefikasian vaksin DNA boleh ditingkatkan dengan penyuntikan 
bersama adjuvan Freund dan imunisasi DNA berulang. Percubaan vaksin dalam ayam 
SPF menunjukkan bahawa kedua-dua plasmid DNA bulatan dan terpotong bagi 
pEGFP-N31F menghasllkan antibodi setelah suntikan booster kedua and memberi 
perlindungan 40-47% terhadap saingan NDV. Penyuntikan bersama plasmid-plasmid 
pEGFP-N31F dan -NIIHN menghasilkan antibodi yang berkesan dan memberi lebih 
daripada 50% perlindungan terhadap jangkitan NDV. Tahap antibodi yang terlalu 
sedikit dalam ayam-ayam yang masih hidup mencadangkan bahawa vaksin DNA 
dapat menghasilkan tindakbalas keimunan sel dalam ayam. Keputusan keseluruhan 
juga mencadangkan bahawa kedua-dua DNA F and HN boleh digunakan sebagai 
komponen vaksin untuk memberi perlindungan efektif terhadap jangkitan NDV dan 
imunisasi DNA membuka satu pendekatan barn dalam perkembangan vaksin gen 
untuk ayam daripada dijangkiti penyakit. 
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CHAPTER I 
INTRODUCTION 
Background 
Newcastle disease (ND) continues to be one of the most important constraints 
to the development of improved livestock production in both developing and 
developed countries (Awan et al. , 1994; Maldonado et al., 1994; Alexander, 1995). At 
present, animal husbandry and production industries, particularly in the developing 
countries, are attempting to meet the demands for increased food production from 
expanding human populations. In Peninsular Malaysia, the poultry industry has 
developed to a most scientifically advanced industry and contributes more than 60% 
of the total value of livestock. In order to maintain and increase the productivity of 
poultry products, both the vaccination and therapeutic or prophylactic use of drugs 
play an important role in animal disease control. Now, vaccination is increasingly 
being viewed as the most sustainable option, as it has a major impact on the control of 
epidemic viral disease of livestock such as foot- and-mouth disease (Bachrach et al., 
1975; Di Marchi et al., 1986) and rinderpest (Romero et aI., 1993). Moreover, it has 
the potential to offer for greater economic efficiency in every aspect. 
Vaccination against ND virus (NDV) is a common practice worldwide in the 
poultry industry (Beard and Hanson, 1984; Glisson and Kleven, 1993). In the past 
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decades, protection from NO has traditionally relied on the use of either attenuated or 
killed vaccines. The most widely used vaccines are live viruses consisting of either 
lentogenic or selected meso genic strains propagated in embryonated chicken eggs. 
The most common NDV vaccine strains are V4, Ulster 2C, Hitchner Bl, Asplin F and 
La Sota (all lentogenic) and Roakin, Mukteswar and Komarov (all mesogenic) 
(reviewed in Alexander, 1988). Both the attenuated and killed vaccines have been 
used successfully to induce protective level of immunity among the poultry not only 
in Malaysia, but also in Australia and many other parts of the world where endemic 
NOV is prevalent (Alexander, 1995). Nonetheless, problems may arise in field when 
insufficient attention is paid to factors such as age of the birds, route of inoculation, 
the strains of virus and follow-up serology (Taylor et aI., 1990; Glisson and Kleven, 
1993). For live attenuated vaccine, there is always a degree of unpredictability as it 
may cause clinical disease if not attenuated sufficiently (Mckee et ai., 1987) and most 
importantly, the possibility of reversion to a more virulent potentially disease-causing 
phenotype which can establish persistent or latent infection to the host (Weeks-Levy 
et ai., 1991; Ogra et ai. , 1991). In addition, live recombinant vaccine, which is 
engineered to express recombinant genes of which its products are immunogenic, is 
able to induce both humoral and cell-mediated responses, however, it may not be safe 
for immunocompromised individuals such as AIDS patients. On the other hand, killed 
vaccines are generally safe, but unable to generate protective levels of immunity for 
reasons of losing important epitopes of antigen during inactivation (reviewed in Cox 
et ai., 1993). Moreover, multiple boosters are usually necessary in order to generate 
continual antigen exposure. Furthermore, killed vaccines do not sustain in the host or 
enter into the host cell, therefore, do not synthesize endogenous protein and unable to 
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induce cytotoxic T cells (Monaco, 1992), possibly a desirable property of an effective 
vaccine (Leung and Ada, 1982; Taylor and Askonas, 1986). In addition, killed 
vaccines also have potential risk in which incomplete or improper killing of virus 
could result in the contamination of vaccines with active wild type virus, especially 
during large-scale production of the virus (reviewed in Kang, 1989). 
In the early 1980s, the advent of recombinant DNA technology created 
excitement and provided new opportunities to produce vaccines based on the use of 
expressed products of cloned genes. The approach of using purified recombinant 
proteins or subunit protein vaccines, consisting of non-replicating and non-infectious 
portions of the pathogenic agent, has provided some solutions to problems such as 
incomplete inactivation, unsatisfactory attenuation of the virus and the possible 
biological contamination of the vaccines that may occur during large-scale production 
of virus. The use of purified recombinant proteins. for vaccination has shown success 
where the immunity has been achieved with antigen produced in Escherichia coli, 
yeast or other euk;aryotic systems (McAleer et ai., 1984; Willadsen et ai. , 1989; 
Musoke et ai., 1992). Recently, the advent of expression vector such as baculoviruses, 
which can produce large quantities of desired proteins in cell culture, has greatly 
enhanced the possibilities for other subunit vaccine development (Miller, 1988; 
Marshall and Roy, 1990; Pearson and Roy, 1993). Undoubtedly, subunit protein 
vaccines are safe to use. However, they are easily denatured during purification and 
are not always in their native form when introduced into the host (Finn, 1998), hence, 
making them poorly immunogenic. 
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Despite the effectiveness of the current vaccines, many such vaccines are still 
inadequate for the reasons of safety, cost effectiveness and efficacy related to the risk 
of infection from the emergence of vaccine-escape mutant (Carman et ai., 1990). 
Therefore, further development of new vaccines to improve the efficacy of 
vaccination is desirable. At present, direct gene transfer into mammalian somatic 
tissue in vivo is a powerful approach for gene therapy with potential application. 
Within a decade, the field of genetic vaccination has been studied and developed 
rapidly and has taken on a new urgency as the vulnerability of related populations to 
infectious disease increases. The development of DNA vaccine against viral infection 
has become a great surprise and challenge in the molecular medicine after its first 
introduction by Wolff et al. in 1990 as DNA vaccines can induce both humoral and 
cell-mediated immunity. Since then, immunization by direct injection of DNA has 
been working out towards the induction of protective antiviral immunity in the animal 
models (Ulmer et al., 1993; Yokoyama et al., 1995.; Armas et aI., 1996; Sakaguchi et 
ai., 1996; Chow et ai., 1997). 
Direct injection of DNA into animals can result in immune responses to 
protein encoded by DNA. Although this vaccination strategy is relatively new, it has 
already been shown to be successful in generating protective immunity against 
influenza virus (Ulmer et aI., 1993; Larsen et ai., 1998), rotavirus (Herrmann et ai., 
1996), lymphocytic choriomeningitis virus (Pedroza et ai., 1995; Yokoyama et ai., 
1995), herpes simplex virus (Manickan et ai., 1995; Bourne et ai., 1996; Mangala et 
ai., 1998) and hepatitis B virus (Triyatni et ai., 1998). Like live-virus vaccines, DNA 
vaccines can induce both antibody and T-cell responses. The latter comprises both 
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major histocompatability complex (MHC) class II-restricted CD4+ T cells, most often 
of helper phenotype and MHC class I-restricted CD8+ cytotoxic T- lymphocytes 
(CTLs), which kill or lyse infected cells by means of the action of protein petforin 
released by CD8+ CTLs (reviewed in Griffiths and Tschopp, 1995). CD8+ CTLs have 
been demonstrated to be a major host defence mechanism against many viruses since 
the last two decades (yap et ai., 1978; Buchmeier et ai., 1980; Lin and Askonas, 
1981; Kast et ai., 1986). However, the importance of CTL response induced by DNA 
vaccine was only highlighted recently (Doe et ai., 1996; Iwasaki et ai., 1997a; Ulmer 
et ai., 1998). At present, DNA-based immunization has yet been applied to human 
commercially, however, clinical trials on human have been underway (Finn, 1998; 
Wang et al., 1998). There are many potential problems related to the use of DNA 
vaccines. For example, the expression of vector derived antigens may negatively 
influence the specific immune response in the host; the possibility of insertional 
mutagenesis that occur may lead to the unpredictable side effects such as switching on 
or off of oncogenes and tumor suppressor genes (reviewed in McDonnell and Askari, 
1996). Therefore, the safety of using DNA vaccine remains an issue. Still, DNA 
vaccination is likely to become a valuable tool for diverse types of therapeutic 
interventions. 
Significance of the Study 
In the present study, we intended to develop DNA vaccines against the 
Malaysian heat resistant viscerotropic-velogenic Newcastle disease virus (NDV) 
strain AF2240 with both the fusion (F) and heamagglutinin- neuraminidase (HN) 
